Where is Mundipharma Pty headquartered?

Mundipharma Pty Limited is recorded with headquarters in Sydney, AU in NovaPharmaNews public regulatory and sponsor datasets.

Is Mundipharma Pty publicly traded?

Mundipharma Pty is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Mundipharma Pty?

We link 3 drug profile(s) where Mundipharma Pty appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Mundipharma Pty sponsoring?

Mundipharma Pty is linked to 4 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Mundipharma Pty as applicant?

No US patent records are currently linked to this company profile.

What therapeutic areas does Mundipharma Pty target?

Indications and classes aggregated from linked trials and drugs: Osteoarthritis, Pain, Chronic pulmonary aspergillosis (CPA).

What pipeline phases does Mundipharma Pty have in our database?

Phase distribution from linked programs: approved: 1, phase 1: 1, phase 3: 1, phase 2: 1.

How many US-approved drugs are linked to Mundipharma Pty?

2 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Mundipharma Pty hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Mundipharma Pty?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Mundipharma Pty data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Mundipharma Pharmaceuticals Company Profile

Name: Mundipharma intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Sydney, AU
Founded: 1952
Employees: 2,082
Programs: 4
Drugs: 23
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Mundipharma Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Osteoarthritis, Pain, Chronic pulmonary aspergillosis (CPA). NovaPharmaNews links 4 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1), phase 1 (1), phase 3 (1).

Company snapshot

Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management and Infectious Disease, as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are

3 approved product(s) across US/EU regulatory metadata.
4 active pipeline program(s) linked via ClinicalTrials.gov.
4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Mundipharma. Not investment advice.

Top assets

View drugs (23) View projects (4)

Lead pipeline drugs

aspirin
approved
atropine sulfate
approved
buprenorphine
approved
capsule
Marketed / approved

Active clinical programs

CD101.IV.3.08 Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)
Phase 3
REZZAYO 200 mg powder for concentrate for solution for infusion Chronic pulmonary aspergillosis (CPA)
Phase 2
Oxycodone (OxyNorm®) Injection Pain
Phase 1
Buprenorphine transdermal patch Osteoarthritis
Approved

Momentum

Proprietary activity score for Mundipharma.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 2 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Amneal Pharma Europe

TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Mundipharma.

Jun 8, 2026 Clinical update
CD101.IV.3.08 — Phase 3
Jun 8, 2026 Clinical update
Oxycodone (OxyNorm®) Injection — Phase 1
Jun 8, 2026 Clinical update
REZZAYO 200 mg powder for concentrate for solution for infusion — Phase 2
May 26, 2026 Clinical update
Buprenorphine transdermal patch — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Mundipharma?

Mundipharma Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Osteoarthritis, Pain, Chronic pulmonary aspergillosis (CPA). NovaPharmaNews links 4 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from pub
Is Mundipharma publicly traded?

Mundipharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does Mundipharma develop or market?

We link 23 drug profile(s) where Mundipharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mundipharma-gmbh#company-drugs.
What are the latest developments for Mundipharma?

In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Mundipharma focus on?

Mundipharma focuses on Osteoarthritis, Pain, Chronic pulmonary aspergillosis (CPA) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease

Neurology